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u and Amidon described an extended 
compartmental absorption and transit 
(CAT) model to estimate saturable small 
intestinal absorption. This model simultaneously 
considers passive absorption, saturable 
absorption, degradation, and transit kinetics in 
the human small intestine Cefatrizine. is an 
Amino ’’β- lactam antibiotics ’’ that is absorbed 
by a carrier mediated system (through carriers), 
it means that follows saturated absorption and 
might be dose dependent absorption and might 
be dose dependent absorption to some extent. 
This type of absorption cannot be explained 
linear absorption model. This model must be 
mechanistic and quantitative to estimate dose 
dependent absorption and degradation in vivo. 
No saturated absorption occurs in ileum except 
the first compartment in which transporters 
continue to decrease from jejunum to ilium. 
Gastric emptying is considered to be first order, if 
residence time is 0.25h. 
By coupling intravenous pharmacokinetics 
parameters with the extended CAT model, it can 
be determined the plasma concentration time 
profile. Plasma concentration time profiles were 
determined at three doses 250, 500 and 1000 
mg in order to use CAT model to predict the dose 
dependent absorption. Predicted plasma 
concentrations were 4.3. 7.9 and 9.3 µm/ ml at 
peak times 1.6 ,1.8 and 2.0 h in line with the 
experimental mean peak plasma concentration 
4.9±1.2 , 8.6± 1.0 and 10.2 ± 2.1 µg/ ml at the 
peak times 1.4±0.4, 1.6±0.2 and 2.0±0.6 hr. 
Reported absolute bioavailability was 75% and 
50% at 250 and 1000 mg oral doses which are 
compared with theoretically determined 
fraction of dose absorbed. 
Calculated fraction of dose absorbed is lower 
than calculated bioavailability at dose 500mg so, 
experimentally determined data is compared 
with predicted data at three doses of cefatrizine 
250, 500 and 1000mg. 
All pharmacokinetic parameters AUC, urinary 
excretion, fraction of dose in colon, fraction of 
dose degraded, reported in feces. 
The literature data vary significantly for all these 
model parameters, so these variations affect the 
“prediction result”. Because of the large 
variations of these parameters, only one 
standard deviation changes were 
simulated, %age changes in the fraction of dose 
absorbed.  
As a result of these simulation changes no single 
factor results in over 25% variation in the 
fraction of dose absorbed. In this way, no single 
physiological factor could account for such a 
large difference in literature data .However, the 
overall effect of these physiological factors could 
account for up to 40% variability in 
bioavailability. 
The MM model was statistically significant over 
models incorporating either first or zero order 
absorption; however this model fails to explain 
the reduced extent of absorption at high doses. 
This MM model does not consider effect of 
degradation; it cannot be compared CAT model 
with MM model. 
Mechanical and quantitative absorption model 
which can simultaneously be consider passive 
absorption, saturated absorption, degradation 
and transit in the human small intestine. But 
this model does not explain the large differences 
in fraction of dose absorbed which were 
explained by extended CAT model. Extended CAT 
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model is only useful; if it is considered that no 
metabolism occurs. 
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